5 AI pharma marketing tools clients swear by in 2025

5 AI pharma marketing tools clients say actually work

2025 was the year AI stopped being a pet project and became part of the marketing team. In the MM+M/Publicis Health 2025 Innovation Survey, one-third of respondents said they're "right where they need to be" with AI and 40% said it's "deeply embedded" in daily workflow-both big jumps from 2024.

Spending followed. One study pegs healthcare AI investment at $1.4B in 2025, nearly triple 2024. Patient and payer engagement alone rose to $175M from $30M. Below are five agentic tools in active use that clients credit with real results.

Lirio: Digital nudges that make healthy actions routine

Lirio blends AI with behavioral science to send hyper-relevant prompts-think: refill reminders, BP checks, appointment scheduling. It learns which channels and messages each person responds to and refines every touch, right down to button copy and imagery.

• Where it fits: Payers and health systems wanting scalable engagement without piling more tasks on care teams.
• Proof: Cone Health reached 9,700 patients for hypertension checks; 6,100 kept appointments and 40% improved BP. For diabetes: 4,700 reached, 2,500+ appointments kept, 54% improved A1C.

Invoca: Call intelligence that closes the loop

Invoca connects your media, web, and call center data to attribute calls, extract first-party insights, and improve outcomes-HIPAA-compliant. It often doubles call center close rates and lifts paid search conversions by surfacing intent and routing callers based on sentiment and topic analysis.

• Where it fits: Health systems and providers who depend on inbound calls to book appointments and convert service lines.
• Proof: Christus Health uses Invoca to track patients from top-of-funnel through the call center, distinguish new vs. existing patients, and identify cross-sell paths-turning anecdote into measurable ROI.

For privacy guidance, see HIPAA basics from HHS: HHS HIPAA.

Axonal.AI: Evidence-first decision systems for regulated work

Axonal.AI isn't another chatbot. It's an enterprise layer built on "evidence first" logic that uses specialist agent swarms-strategy, analytics, planning-to produce defensible outputs that stand up to MLR review. The flagship, Strategist+, "kills the blank page" by pulling secure internal data (e.g., Snowflake) and external signals to draft strategy foundations in minutes.

This evidence-first approach aligns with curated Research on model validation and regulatory readiness.

• Where it fits: Brand, insights, and market planning teams needing faster, audit-ready decisions.
• Proof: With The Considered, teams pressure-tested positioning territories against likely market futures (2026-2029). One strategy looked strong early but faded by 2027; another overtook it by 2028-insight delivered in 15-minute cycles instead of months.
• Metric that matters: Time to Insight-compressing research from weeks to hours shortens the path to market.

Odaia.ai: A rep's living call plan and brand execution layer

Odaia's MAPTUAL platform sits on top of scripts, claims, activity, marketing interactions, and third-party data to predict HCP and patient behavior. It ranks HCPs by likelihood to engage, preferred channels, and next best actions-updating as new data flows in.

• Where it fits: Commercial teams that want dynamic call lists, better field context, and reduced prep time.
• What's smart: Generative summaries prep reps with recent HCP activity and likely objections; embedded insights inside Veeva and Salesforce keep recommendations where work happens. Clients include GSK, Novo Nordisk, and Verona.
• For marketers: Orchestrates personal and non-personal outreach and measures downstream impact so strategy doesn't drift in the field.

Publicis Health + Razorfish: Making sense of the FDA's warning-letter spree

After the FDA issued a wave of DTC advertising warning letters in September, Publicis Health and Razorfish spun up Next DTC-an AI tool trained on ~300 letters-to spot patterns by product, claim, and channel. Strategy and creative teams use it to identify "watch outs" and stress test concepts before they ship.

• What's changing: Fewer distractions during safety VO, bigger fonts, and more conservative efficacy claims-clear themes in recent letters and responses.
• What's next: Ongoing ingestion of new and close-out letters, plus scenario workshops (e.g., stricter rules on influencers or changes to adequate provision) to plan media and messaging moves.

See FDA's letters and guidance hub: FDA Advertising and Promotion Letters.

How to choose your stack: a quick checklist

• Data access: Can it integrate with your DWH/CRM (e.g., Snowflake, Veeva, Salesforce) without months of plumbing?
• MLR readiness: Are outputs traceable, source-cited, and reviewable? "Fluent" is useless if it's not defensible.
• Privacy/compliance: HIPAA, audit trails, PHI handling, and clear governance.
• Measurable impact: Define the primary metric now (appointments, close rates, TTI, adoption) and set a baseline.
• Adoption: Do insights show up inside existing workflows so teams actually use them?

The bottom line

These five tools don't promise magic. They shorten the path from data to action, cut decision lag, and keep teams aligned-where the ROI actually comes from.

If you're upskilling teams on practical AI for go-to-market and field execution, consider the AI Learning Path for Business Unit Managers as a curated starting point.